AbCellera Biologics Inc Ordinary Shares ABCL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
AbCellera Reports Q2 2026 Business Results
-
AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions
-
An AI Biotech Just Reported a 46% Revenue Jump and Its First Recurring Platform Contracts, as Its Pivot Starts Showing Up in the Numbers
-
As AI Rewrites Drug Discovery, This Bio-Native AI Company Just Joined the Russell 3000E, and Reports Earnings July 22
-
AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026
-
AbCellera Appoints Dr. Lynn Seely to its Board of Directors
-
As AI Models Become Commodities, One Bio-Native AI Company Just Moved to Patent the Thing That Actually Compounds: the Data
-
Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies
Trading Information
- Previous Close Price
- $5.92
- Day Range
- $5.62–6.57
- 52-Week Range
- $2.75–8.44
- Bid/Ask
- $6.57 / $6.60
- Shares Outstanding
- 305.38M
- Market Cap
- $1.99B
- Volume/Avg
- 31,738 / 7M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 29.83
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 562
- Website
- https://www.abcellera.com
Valuation
|
Metric
|
ABCL
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.23 |
Price/Sales | 29.83 |
Price/Cash Flow | — |
Price/Earnings
ABCL
Financial Strength
|
Metric
|
ABCL
|
|---|---|
Quick Ratio | 11.95 |
Current Ratio | 12.77 |
Interest Coverage | — |
Quick Ratio
ABCL
Profitability
|
Metric
|
ABCL
|
|---|---|
Return on Assets (Normalized) | −9.06% |
Return on Equity (Normalized) | −12.77% |
Return on Invested Capital (Normalized) | −12.38% |
Return on Assets
ABCL
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|t%Dn%$ | LOCK|G>v> | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|#Z?$SZD | LOCK|XNWW | $79B | |||
| argenx SE ADR
ARGX
| LOCK|^?mjZ$l | LOCK|$>c | $54B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|!P@@VYxS | LOCK|b<Ym$ | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|<w?Yj^b | LOCK|PfH | $39B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|SS@$$bC | LOCK|Y>M@ | $31B | |||
| Incyte Corp
INCY
| LOCK|T@Y^H^ | LOCK|ND | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|@%bDV?$ | LOCK|##! | $23B | |||
| Moderna Inc
MRNA
| LOCK|G&<tsRq | LOCK|P^m | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|M$<xvG# | LOCK|?@> | $17B |
United States